About Immunicum
Immunicum is a publicly listed company based in Goteborg (Sweden) founded in 2002. Allogeneic dendritic cells based vaccines, T-cell therapy for the treatment of cancer. Immunicum has completed 1 acquisition, including DCprime. Immunicum offers products and services including Vididencel. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
Immunicum was founded in 2002 in Gothenburg, Sweden, within the biotechnology sector focused on cancer immunotherapy. Therapeutic vaccines and treatments are developed using platforms such as COMBIG for allogeneic dendritic cell products like INTUVAX and SUBCUVAX, which target tumors through intratumoral or subcutaneous administration. The CD70 platform is utilized to enhance CAR-T cell expansion and longevity for adoptive cell therapy in cancer patients.
- Headquarters Goteborg, Sweden
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website immunicum.se
- Social LinkedIn
- Latest Funding Round$38.57M (USD), Post-IPO
Dec 2018
- Investments & Acquisitions
Products & Services of Immunicum
Immunicum offers a comprehensive portfolio of products and services, including Vididencel.
Therapy for Acute Myeloid Leukemia to reduce tumor recurrence.
Funding Insights of Immunicum
- Total Rounds 1
- Last Round Post-IPO — $38.57M
- First Round $38.57M
(Dec 2018)
All 1 funding rounds of Immunicum with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2018 | $38.57M | Post-IPO | – | – | – |
Investments & Acquisitions by Immunicum
Immunicum has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include DCprime.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Novel cancer immunotherapies are developed using the DCOne platform. | dcprime.com | Leiden, Netherlands | 2005 | Nov 2020 | •••• |
Complete acquisition details for Immunicum
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Immunicum
4 dated milestones of Immunicum across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Immunicum is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $38.6M.
- Acquisition Acquires DCprime.
Web traffic of Immunicum
Websites that share an audience with Immunicum (immunicum.se).
Websites whose visitors overlap most with Immunicum. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
sjukhuslakaren.se | sjukhuslakaren.se | 100% | #1,788,846 | – | |
ctep.cancer.gov | ctep.cancer.gov | 81% | – | ||
firstwordpharma.com | firstwordpharma.com | 80% | #237,108 | – | |
products.sanofi.us | products.sanofi.us | 79% | – | ||
saskcancer.ca | saskcancer.ca | 79% | #1,579,881 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for Immunicum
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Immunicum
Complete news archive for Immunicum
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Immunicum
Immunicum was founded in 2002 and raised its 1st funding round 16 years after it was founded.
Immunicum is headquartered in Goteborg, Sweden. It is registered at Goteborg, Vastra Gotaland, Sweden.
Immunicum was founded in 2002 in Gothenburg, Sweden, within the biotechnology sector focused on cancer immunotherapy. Therapeutic vaccines and treatments are developed using platforms such as COMBIG for allogeneic dendritic cell products like INTUVAX and SUBCUVAX, which target tumors through intratumoral or subcutaneous administration. The CD70 platform is utilized to enhance CAR-T cell expansion and longevity for adoptive cell therapy in cancer patients.
Immunicum offers Vididencel.
Immunicum has made 1 acquisition, including DCprime.